Balchem (NASDAQ:BCPC) has been assigned a $101.00 price objective by stock analysts at HC Wainwright in a research report issued on Tuesday, February 5th. The brokerage presently has a “buy” rating on the basic materials company’s stock. HC Wainwright’s price target points to a potential upside of 11.53% from the stock’s previous close.
Other research analysts also recently issued research reports about the stock. Sidoti upgraded shares of Balchem from a “neutral” rating to a “buy” rating and set a $127.00 price objective on the stock in a research report on Tuesday, October 16th. BidaskClub raised shares of Balchem from a “sell” rating to a “hold” rating in a report on Thursday, October 18th. ValuEngine downgraded Balchem from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Pivotal Research raised Balchem from a “hold” rating to a “buy” rating and upped their target price for the company from $95.00 to $100.00 in a research report on Tuesday, November 6th. Finally, Zacks Investment Research cut Balchem from a “hold” rating to a “sell” rating in a research note on Tuesday, December 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. Balchem currently has an average rating of “Hold” and an average price target of $105.50.
Shares of NASDAQ:BCPC traded up $1.83 during midday trading on Tuesday, hitting $90.56. 152,722 shares of the stock traded hands, compared to its average volume of 88,921. The company has a market cap of $2.80 billion, a price-to-earnings ratio of 30.09 and a beta of 0.91. The company has a current ratio of 3.42, a quick ratio of 2.33 and a debt-to-equity ratio of 0.27. Balchem has a one year low of $73.16 and a one year high of $117.79.
Balchem (NASDAQ:BCPC) last released its quarterly earnings results on Thursday, February 28th. The basic materials company reported $0.77 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.11. Balchem had a net margin of 15.67% and a return on equity of 14.51%. The company had revenue of $163.50 million during the quarter, compared to the consensus estimate of $161.42 million. Balchem’s revenue was up 2.6% on a year-over-year basis. As a group, research analysts forecast that Balchem will post 2.98 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. NumerixS Investment Technologies Inc bought a new position in shares of Balchem in the 4th quarter valued at $39,000. Pearl River Capital LLC acquired a new stake in Balchem during the 4th quarter worth about $45,000. Bank of Montreal Can grew its holdings in Balchem by 13.6% during the 4th quarter. Bank of Montreal Can now owns 1,926 shares of the basic materials company’s stock worth $151,000 after acquiring an additional 231 shares during the period. Quantamental Technologies LLC acquired a new stake in Balchem during the 4th quarter worth about $188,000. Finally, Advisor Group Inc. grew its stake in shares of Balchem by 5.5% in the 4th quarter. Advisor Group Inc. now owns 2,470 shares of the basic materials company’s stock valued at $195,000 after buying an additional 128 shares during the period. Hedge funds and other institutional investors own 85.85% of the company’s stock.
Balchem Company Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the food, nutritional, feed, pharmaceutical, medical sterilization, and industrial markets in the United States and internationally. The company's Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Featured Article: Technical Analysis
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.